Cns Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cns Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Cns Pharmaceuticals Inc recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -141.87%.

However, within the Healthcare sector 803 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4433, from total ROA ranking in the first quarter of 2026 at 5045.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	51.21 %	-66.16 %	-0.89 %	60.2 %	487.54 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-17	-16	-16	-13	-15
Return On Assets (TTM)	-141.87 %	-166.3 %	-130.06 %	-107.08 %	-139.37 %
CNSP's Total Ranking	# 4433	# 5045	# 4413	# 4578	# 4741
Total Assets (TTM) in million	22	5	9	12	15
Seq. Total Assets Change	371.46 %	-46.04 %	-27.35 %	-18.19 %	5.52 %
Seq. Net Income Change	-	-	-	-	-

CNSP's 5 Years Annual ROA >> Back to CNSP Management Effectiveness >> Compare CNSP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 378
Sector	# 804
Overall	# 4346

Return On Assets Statistics
High	Average	Low
-104.09 %	-225.7 %	-783.11 %
(Sep 30 2021)		(Jun 30 2024)

News about Cns Pharmaceuticals Inc Return on Assets ROA

CNS Pharmaceuticals Inc. (NASDAQ CNSP) to Present at Virtual Investor Closing Bell Series

In recent news, CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a leading biopharmaceutical company specializing in the development of innovative anti-cancer drug candidates, is set to participate in the upcoming Virtual Investor Closing Bell Series. The company s commitment to advancing its pipeline of potential cancer treatments has garnered attention in the market. Additionally, CNS Pharmaceuticals received a neutral rating from Ladenburg Thalmann, leading to a raised price target for their stock. This article aims to provide an overview of these developments and their potential impact on CNS Pharmaceuticals Inc.CNS Pharmaceuticals Inc. s Participation in the Virtual Investor Closing Bell Series:CNS Pharmaceuticals Inc. is pleased to announce its participation in the Virtual Investor Closing Bell Series, further demonstrating its commitment to engaging with the investment community. The event will provide a platform for the company s Executive to showcase their innovative anti-cancer drug candidates and share valuable insights into its pipeline. This participation highlights CNS Pharmaceuticals dedication to transparency and investor relations, offering the opportunity for shareholders to gain further confidence in the company s growth prospects.

Financial Statements
Cns Pharmaceuticals Inc 's Assets	$ 22 million	CNSP's Balance sheet
Cns Pharmaceuticals Inc 's Income	$ -3 million	Quarterly CNSP's Income Statement
CNSP's Income by Division		See CNSP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-0.89 %	411.56 %	-86.97 %	49.05 %	-44.76 %
Total Assets in million	9	9	2	13	9
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-16	-15	-19	-15	-14
Annual Return On Assets	-183.81 %	-170.76 %	-1108.34 %	-117.01 %	-160.28 %

CNSP's 5 Years Annual ROA >> Back to CNSP Management Effectiveness >> Compare CNSP ROA to its Competitors

More Return On Assets Ratios
CNSP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CNSP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CNSP's Competitors
Subscribers only: Roa for Cns Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for CNSP's Customers

You may also want to know
CNSP's Roi	CNSP's Inventory Turnover Ratio	CNSP's Growth Rates	CNSP's Dividend Comparisons
	CNSP's Profitability Ratios	CNSP's Asset Turnover Ratio	CNSP's Dividend Growth
CNSP's Roe	CNSP's Valuation Ratios	CNSP's Financial Strength Ratios	CNSP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:40:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.